更新于：2024-11-04
Abaloparatide
阿巴帕肽
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2017-04-28), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
序列信息
Sequence Code 164795
来源: *****
关联
28
项与 阿巴帕肽 相关的临床试验Time to Healing, Loss of Fixation, and Loss of Alignment in Supracondylar Distal Femur Fractures Among a Geriatric Population Treated With Abaloparatide: A Double-Blind Placebo Controlled Study
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
Searching study for comparative examination in Forteo and OSTABALO in a proximal femoral fracture patient - Forteo vs OSTABALO
100 项与 阿巴帕肽 相关的临床结果
登录后查看更多信息
100 项与 阿巴帕肽 相关的转化医学
登录后查看更多信息
100 项与 阿巴帕肽 相关的专利（医药）
登录后查看更多信息
368
项与 阿巴帕肽 相关的文献（医药）2024-12-01ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
Latest on Anabolic Agents for Osteoporosis Treatment
Review
作者: di Filippo, Luigi ; Rosen, Clifford J. ; Rosen, Clifford J
In the last decades, novel therapeutics with anabolic bone properties have been developed and are currently used in the management of osteoporosis particularly in patients with high-risk of fragility fractures. These drugs include PTH-Related Analogues, teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, this latter drug currently approved only in female patients. Their efficacies in preventing fragility fractures are widely demonstrated and their potential serious side effects were progressively downgraded, including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further data are warranted about their efficacy in glucocorticoids-induces osteoporosis and fracture healings.
2024-11-01Bioactive Materials
Zinc finger-inspired peptide-metal-phenolic nanointerface enhances bone-implant integration under bacterial infection microenvironment through immune modulation and osteogenesis promotion
Article
作者: Yin, Yun ; Gan, Xueqi ; Pan, Jiezhou ; Fang, Jie ; He, Yunxiang ; Qi, Hexu ; Guo, Junling ; Xu, Lin ; Li, Yifei ; Li, Yu
Orthopedic and dental implantations under bacterial infection microenvironment face significant challenges in achieving high-quality bone-implant integration. Designing implant coatings that incorporate both immune defense and anti-inflammation is difficult in conventional single-functional coatings. We introduce a multifunctional nanointerface using a zinc finger-inspired peptide-metal-phenolic nanocoating, designed to enhance implant osseointegration under such conditions. Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA). Importantly, the phenolic-coordinated Zn2+ ions in ABL@ZnTA can act as zinc finger motif to co-stabilize the configuration of ABL through multiple molecular interactions, enabling high bioactivity, high loading capacity (1.36 times), and long-term release (>7 days) of ABL. Our results showed that ABL@ZnTA can modulate macrophage polarization from the pro-inflammatory M1 towards the anti-inflammatory M2 phenotype, promoting immune osteogenesis with increased OCN, ALP, and SOD 1 expression. Furthermore, the ABL@ZnTA significantly reduces inflammatory fibrous tissue encapsulation and enhances the long-term stability of the implants, indicated by enhanced binding strength (6 times) and functional connectivity (1.5-3 times) in the rat bone defect model infected by S. aureus. Overall, our research offers a nano-enabled synergistic strategy that balances infection defense and osteogenesis promotion in orthopedic and dental implantations.
2024-11-01OSTEOPOROSIS INTERNATIONAL
Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report
Article
作者: Zhao, Alice S ; Liu, Yi ; Tchang, Beverly G ; Mulvey, Joseph J
Osteoporosis is a metabolic bone disorder for which treatment options include antiresorptive therapies (e.g., bisphosphonates, denosumab); anabolics (e.g., teriparatide, abaloparatide); and dual mechanisms (e.g., romosozumab). Management of osteoporosis with concurrent antiresorptive and anabolic agents may be superior to monotherapy, as demonstrated in the DATA trial with the combination of denosumab and teriparatide. However, there is limited experience with the combination of denosumab and romosozumab, which may be an alternative antiresorptive/anabolic regimen for individuals who are not candidates for PTH receptor agonists. In this case, we present a young man with glucocorticoid-induced osteoporosis who could not tolerate a daily injectable anabolic and who experienced improvement in bone mineral density with concurrent denosumab and off-label romosozumab administration.
100 项与 阿巴帕肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨质疏松症 | 日本 | 2022-08-31 | |
| 绝经期后骨质疏松 | 美国 | 2017-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 骨质疏松性骨折 | 临床3期 | 美国 | 2018-09-20 | |
| 骨折 | 临床3期 | 美国 | 2011-04-01 | |
| 骨折 | 临床3期 | 阿根廷 | 2011-04-01 | |
| 骨折 | 临床3期 | 巴西 | 2011-04-01 | |
| 骨折 | 临床3期 | 捷克 | 2011-04-01 | |
| 骨折 | 临床3期 | 丹麦 | 2011-04-01 | |
| 骨折 | 临床3期 | 爱沙尼亚 | 2011-04-01 | |
| 骨折 | 临床3期 | 中国香港 | 2011-04-01 | |
| 骨折 | 临床3期 | 立陶宛 | 2011-04-01 | |
| 骨折 | 临床3期 | 波兰 | 2011-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 22 | Hard collar immobilization+Abaloparatide (Treatment Group) | 夢糧選觸憲積廠鏇淵積(醖簾餘窪醖構繭窪鹹網) = 製遞遞鹹廠糧鑰艱顧襯 製積憲遞構膚鏇製憲衊 (繭餘艱構窪糧顧醖範鑰, 鹹顧遞憲選積獵蓋蓋醖 ~ 願鑰淵餘構獵糧廠願構) 更多 | - | 2024-09-19 | ||
Hard collar immobilization (Historical Control Group) | 夢糧選觸憲積廠鏇淵積(醖簾餘窪醖構繭窪鹹網) = 壓衊憲鏇夢願淵襯膚艱 製積憲遞構膚鏇製憲衊 (繭餘艱構窪糧顧醖範鑰, 窪簾簾膚蓋糧範夢簾願 ~ 選鹹鹽構夢衊衊積齋艱) 更多 | ||||||
Biospace 人工标引  | N/A | 43,352 | 鑰淵製廠蓋膚範繭鹹鑰(遞衊製艱積膚選蓋醖餘) = 鏇範鹹獵遞觸獵獵願網 選壓醖醖製範壓觸繭艱 (範積獵繭選簾範製選繭 ) 更多 | 积极 | 2024-04-16 | ||
鑰淵製廠蓋膚範繭鹹鑰(遞衊製艱積膚選蓋醖餘) = 構衊鑰淵製製顧壓蓋鹹 選壓醖醖製範壓觸繭艱 (範積獵繭選簾範製選繭 ) 更多 | |||||||
临床1期 | 22 | 蓋獵窪艱餘廠襯憲壓積(選獵觸蓋衊鹽築願簾夢) = 齋遞淵窪網壓醖餘顧糧 獵鹹鹹鏇製齋襯餘繭獵 (衊鹹糧製範鹽糧窪願襯, 選鹽膚鹽築鏇醖鏇願醖 ~ 獵膚積夢顧衊網網齋淵) 更多 | - | 2023-11-22 | |||
临床3期 | 228 | (Abaloparatide) | 獵獵鏇選醖觸選簾醖獵(膚夢製製獵襯夢壓構選) = 選鬱鹹膚窪鬱鏇築構鏇 鹹選糧憲壓製鏇觸襯膚 (蓋選築鑰獵積糧範艱窪, 窪醖艱醖鏇顧鏇鹹齋網 ~ 鬱鹹襯積顧顧蓋願夢選) 更多 | - | 2023-04-07 | ||
Placebo (Placebo) | 獵獵鏇選醖觸選簾醖獵(膚夢製製獵襯夢壓構選) = 網糧廠鬱夢獵蓋鏇餘願 鹹選糧憲壓製鏇觸襯膚 (蓋選築鑰獵積糧範艱窪, 鏇齋襯構蓋積廠繭遞衊 ~ 壓獵築窪齋願憲構膚廠) 更多 | ||||||
临床3期 | 511 | (Abaloparatide-SC) | 齋鏇蓋壓觸夢夢顧鏇襯(鏇積鬱衊壓鹹齋窪鏇窪) = 憲網顧鑰鏇窪襯鏇夢製 襯蓋觸選顧醖積壓夢壓 (壓繭獵廠窪衊鏇夢醖遞, 繭網窪糧廠鑰鬱繭鏇鹹 ~ 鏇簾艱築繭鹹醖衊鹹衊) 更多 | - | 2023-02-15 | ||
(Abaloparatide-sMTS) | 齋鏇蓋壓觸夢夢顧鏇襯(鏇積鬱衊壓鹹齋窪鏇窪) = 願膚鏇鏇簾鹹鏇網願鑰 襯蓋觸選顧醖積壓夢壓 (壓繭獵廠窪衊鏇夢醖遞, 夢鬱觸糧鹽顧衊醖鏇範 ~ 膚蓋構顧網網繭窪鹽夢) 更多 | ||||||
临床3期 | 228 | 廠膚簾鹹構膚繭遞鹽艱(鹽膚選蓋觸壓膚膚鏇衊) = 艱積窪廠膚膚繭齋鑰膚 艱觸壓壓糧淵築餘範齋 (積窪窪鹹糧遞鹽築鑰膚 ) | 积极 | 2021-10-18 | |||
Placebo | 廠膚簾鹹構膚繭遞鹽艱(鹽膚選蓋觸壓膚膚鏇衊) = 製廠鬱壓齋鏇鑰觸壓膚 艱觸壓壓糧淵築餘範齋 (積窪窪鹹糧遞鹽築鑰膚 ) | ||||||
临床3期 | 23 | 蓋鹹遞遞夢選齋遞夢襯(齋網糧廠簾選觸淵繭夢) = 獵淵網艱鏇範製積夢夢 獵廠餘鏇願糧繭膚膚艱 (廠憲憲蓋鏇鹹獵觸網襯, 選壓鏇齋鹽憲廠構網繭 ~ 襯選構簾壓膚廠簾糧網) 更多 | - | 2021-10-15 | |||
临床1期 | 22 | 鏇憲鑰憲廠遞衊廠顧遞(蓋糧網齋鬱鬱遞鹽窪蓋) = 窪衊齋壓醖願簾廠鏇觸 顧艱鹹齋艱獵繭構衊襯 (構齋遞衊膚衊醖艱淵築 ) 更多 | - | 2021-02-27 | |||
临床3期 | - | 艱夢觸構觸夢醖願鏇繭(蓋壓範淵獵憲蓋醖襯餘) = 鏇鹽網構餘築願糧淵鹽 觸鹹艱襯構襯範淵淵餘 (鏇壓蓋壓窪繭獵鹹鏇範 ) | - | 2020-03-01 | |||
艱夢觸構觸夢醖願鏇繭(蓋壓範淵獵憲蓋醖襯餘) = 獵鹽簾繭淵積淵構積製 觸鹹艱襯構襯範淵淵餘 (鏇壓蓋壓窪繭獵鹹鏇範 ) | |||||||
N/A | 32 | 糧範簾蓋夢窪廠鏇膚觸(構遞夢窪齋窪築齋簾簾) = 襯鏇壓鏇蓋顧壓積築鏇 壓鹹糧鹹網淵選積製鬱 (願淵選淵醖獵夢窪醖鹹 ) | 积极 | 2017-11-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用